Antibody new drug Su Lixin has been approved for sale to regulate the "out-of-control" immune system.

Medicine Network September 4th 3rd, the all-human source IgG1 monoclonal antibody drug Su Lixin obtained the listing approval of the State Drug Administration, will be used to treat rheumatoid arthritis, strong spina bifida, psoriasis.
" drug uses the world's leading sensitive and efficient 'Stateof Art' bioanalytical approach to multi-dimensional studies of the properties, activity and structure of molecules to ensure the screening of high-quality pharmaceutical molecules.
," said Amy Guo, head of pharmacy at the Surissin project and vice president of Xinda Bio's international division.
auto-rheumatoid immune disease refers to the body's immune response to its own tissues, resulting in damage to its own tissues caused by the disease.
In layman's terms, the immune system constitutes a defense system for human health, but it is not 100 percent intelligent, and they are sometimes lured by "foreign bodies" in the body and normal organizational structures, disorders occur, and "guard wars" are carried out, which backfires and produces an immune response.
specifically, inflammatory cytokines such as TNF-alpha are released and "non-differentiated attacks" are carried out on normal tissues, damaging normal organs and leading to rheumatoid immune diseases such as severe spina bificitis.
Surisin is an all-human source IgG1 monoclonal antibody drug that binds to and neutralizes TNF-alpha, which allows the immune system to truly act as a "master guard" by reducing the concentration of TNF-alpha factors in the patient, thus allowing inflammation of autouric immunologic diseases to be well suppressed.
August 2019, three key studies in patients with severe spina bifida were published in the international journal Lancet Rheumatology.
, lead researcher at Tsinghua University and a professor at Tsinghua University's School of Medicine, said: "This is exciting news for The Rheumatology community in China.
", there are nearly 20 million people with rheumatoid arthritis, severe spina bifiditis and psoriasis in China.
autoimmune diseases are not fatal, but they cause great pain and physiological distortion, which seriously affects the quality of life of patients.
said that when it available, It will provide patients with affordable, high-quality biologics that will allow them to treat them in a long-term, standardized way.
Su Lixin is the third monoclonal antibody drug approved by Xinda Bio after Daboshu and Dayu Tong, and has been specially supported by the national "major new drug creation" technology.
(Complete)